Myriad Genetics Stock Total Asset

MYGN Stock

USD 23.26 0.10 0.43%

Myriad Genetics fundamentals help investors to digest information that contributes to Myriad Genetics' financial success or failures. It also enables traders to predict the movement of Myriad Stock. The fundamental analysis module provides a way to measure Myriad Genetics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Myriad Genetics stock.

	Last Reported	Projected for Next Year
Total Assets	1.4 B	1.4 B
Intangibles To Total Assets	0.50	0.34

As of the 28th of May 2024, Total Assets is likely to grow to about 1.4 B, while Intangibles To Total Assets are likely to drop 0.34.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Myriad Genetics Company Total Asset Analysis

Myriad Genetics' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Total Asset

Tangible Assets

+

Intangible Assets

More About Total Asset | All Equity Analysis

Current Myriad Genetics Total Asset

1.2 B

Most of Myriad Genetics' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Myriad Genetics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Myriad Total Asset Driver Correlations

Understanding the fundamental principles of building solid financial models for Myriad Genetics is extremely important. It helps to project a fair market value of Myriad Stock properly, considering its historical fundamentals such as Total Asset. Since Myriad Genetics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Myriad Genetics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Myriad Genetics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Net Receivables	Short Term Investments	Common Stock	Property Plant Equipment	Current Deferred Revenue	Intangible Assets	Net Tangible Assets	Good Will	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Accumulated Depreciation	Long Term Debt Total	Net Invested Capital	Short Long Term Debt	Net Working Capital	Capital Stock
Total Assets		0.83	0.43	-0.37	0.81	0.9	0.22	0.1	0.76	-0.25	0.6	0.6	-0.6	0.89	-0.77	0.88	0.84	0.63	-0.45	-0.72	0.62	0.46	-0.8	0.69	0.45
Total Stockholder Equity	0.83		0.2	-0.11	0.93	0.65	0.41	0.31	0.93	-0.1	0.76	0.3	-0.67	0.76	-0.57	0.76	0.78	0.51	-0.29	-0.73	0.49	0.52	-0.61	0.51	0.24
Net Debt	0.43	0.2		-0.2	0.38	0.45	-0.4	0.05	0.32	-0.35	-0.07	0.5	-0.17	0.46	-0.47	0.55	0.42	0.37	-0.37	-0.07	0.5	0.33	-0.41	0.01	0.25
Retained Earnings	-0.37	-0.11	-0.2		-0.22	-0.39	0.14	0.74	0.05	0.22	-0.3	-0.89	0.18	-0.18	0.2	-0.22	-0.58	0.01	0.28	0.18	-0.6	0.4	0.5	-0.32	-0.89
Accounts Payable	0.81	0.93	0.38	-0.22		0.64	0.18	0.21	0.9	-0.29	0.62	0.45	-0.61	0.78	-0.61	0.81	0.82	0.5	-0.46	-0.77	0.57	0.48	-0.64	0.45	0.33
Total Liab	0.9	0.65	0.45	-0.39	0.64		-0.01	-0.1	0.58	-0.49	0.34	0.52	-0.29	0.92	-0.89	0.89	0.82	0.69	-0.54	-0.57	0.69	0.47	-0.74	0.7	0.43
Total Current Assets	0.22	0.41	-0.4	0.14	0.18	-0.01		0.36	0.37	0.79	0.71	-0.12	-0.53	-0.1	0.29	-0.17	-0.01	-0.13	0.65	-0.18	0.02	0.05	0.05	0.11	-0.05
Short Term Debt	0.1	0.31	0.05	0.74	0.21	-0.1	0.36		0.52	0.34	0.23	-0.49	-0.49	0.1	-0.08	0.11	-0.28	0.22	0.15	-0.32	-0.41	0.4	0.31	-0.28	-0.69
Net Receivables	0.76	0.93	0.32	0.05	0.9	0.58	0.37	0.52		-0.07	0.7	0.19	-0.73	0.71	-0.58	0.73	0.62	0.53	-0.23	-0.77	0.38	0.52	-0.4	0.26	0.05
Short Term Investments	-0.25	-0.1	-0.35	0.22	-0.29	-0.49	0.79	0.34	-0.07		0.39	-0.22	-0.36	-0.6	0.7	-0.61	-0.47	-0.44	0.87	0.26	-0.33	-0.3	0.41	-0.35	-0.18
Common Stock	0.6	0.76	-0.07	-0.3	0.62	0.34	0.71	0.23	0.7	0.39		0.36	-0.87	0.31	-0.17	0.31	0.49	0.13	0.12	-0.57	0.33	-0.01	-0.3	0.22	0.37
Property Plant Equipment	0.6	0.3	0.5	-0.89	0.45	0.52	-0.12	-0.49	0.19	-0.22	0.36		-0.37	0.38	-0.34	0.45	0.71	0.12	-0.39	-0.3	0.65	-0.2	-0.69	0.39	0.88
Current Deferred Revenue	-0.6	-0.67	-0.17	0.18	-0.61	-0.29	-0.53	-0.49	-0.73	-0.36	-0.87	-0.37		-0.31	0.25	-0.37	-0.35	-0.21	0.0	0.69	-0.14	-0.02	0.22	-0.05	-0.19
Intangible Assets	0.89	0.76	0.46	-0.18	0.78	0.92	-0.1	0.1	0.71	-0.6	0.31	0.38	-0.31		-0.94	0.99	0.82	0.75	-0.68	-0.67	0.57	0.64	-0.75	0.68	0.25
Net Tangible Assets	-0.77	-0.57	-0.47	0.2	-0.61	-0.89	0.29	-0.08	-0.58	0.7	-0.17	-0.34	0.25	-0.94		-0.94	-0.68	-0.74	0.77	0.64	-0.46	-0.5	0.59	-0.52	-0.2
Good Will	0.88	0.76	0.55	-0.22	0.81	0.89	-0.17	0.11	0.73	-0.61	0.31	0.45	-0.37	0.99	-0.94		0.83	0.75	-0.73	-0.68	0.55	0.58	-0.76	0.61	0.3
Capital Surpluse	0.84	0.78	0.42	-0.58	0.82	0.82	-0.01	-0.28	0.62	-0.47	0.49	0.71	-0.35	0.82	-0.68	0.83		0.48	-0.54	-0.54	0.81	0.34	-0.87	0.68	0.68
Deferred Long Term Liab	0.63	0.51	0.37	0.01	0.5	0.69	-0.13	0.22	0.53	-0.44	0.13	0.12	-0.21	0.75	-0.74	0.75	0.48		-0.5	-0.46	0.17	0.51	-0.43	0.41	0.03
Long Term Investments	-0.45	-0.29	-0.37	0.28	-0.46	-0.54	0.65	0.15	-0.23	0.87	0.12	-0.39	0.0	-0.68	0.77	-0.73	-0.54	-0.5		0.46	-0.26	-0.25	0.53	-0.42	-0.25
Accumulated Depreciation	-0.72	-0.73	-0.07	0.18	-0.77	-0.57	-0.18	-0.32	-0.77	0.26	-0.57	-0.3	0.69	-0.67	0.64	-0.68	-0.54	-0.46	0.46		-0.23	-0.3	0.41	-0.4	-0.09
Long Term Debt Total	0.62	0.49	0.5	-0.6	0.57	0.69	0.02	-0.41	0.38	-0.33	0.33	0.65	-0.14	0.57	-0.46	0.55	0.81	0.17	-0.26	-0.23		0.34	-0.66	0.5	0.65
Net Invested Capital	0.46	0.52	0.33	0.4	0.48	0.47	0.05	0.4	0.52	-0.3	-0.01	-0.2	-0.02	0.64	-0.5	0.58	0.34	0.51	-0.25	-0.3	0.34		-0.41	0.48	-0.33
Short Long Term Debt	-0.8	-0.61	-0.41	0.5	-0.64	-0.74	0.05	0.31	-0.4	0.41	-0.3	-0.69	0.22	-0.75	0.59	-0.76	-0.87	-0.43	0.53	0.41	-0.66	-0.41		-0.85	-0.61
Net Working Capital	0.69	0.51	0.01	-0.32	0.45	0.7	0.11	-0.28	0.26	-0.35	0.22	0.39	-0.05	0.68	-0.52	0.61	0.68	0.41	-0.42	-0.4	0.5	0.48	-0.85		0.41
Capital Stock	0.45	0.24	0.25	-0.89	0.33	0.43	-0.05	-0.69	0.05	-0.18	0.37	0.88	-0.19	0.25	-0.2	0.3	0.68	0.03	-0.25	-0.09	0.65	-0.33	-0.61	0.41

Click cells to compare fundamentals

Myriad Total Asset Historical Pattern

Today, most investors in Myriad Genetics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Myriad Genetics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Myriad Genetics total asset as a starting point in their analysis.

Myriad Genetics Total Asset

Timeline

Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.

Competition

Predict Myriad Genetics

Total Assets Over Time

Myriad Total Assets

Total Assets

1.45 Billion

At this time, Myriad Genetics' Total Assets are very stable compared to the past year.

Based on the latest financial disclosure, Myriad Genetics has a Total Asset of 1.2 B. This is 84.06% lower than that of the Biotechnology sector and 61.49% lower than that of the Health Care industry. The total asset for all United States stocks is 95.93% higher than that of the company.

Myriad Total Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Myriad Genetics' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Myriad Genetics could also be used in its relative valuation, which is a method of valuing Myriad Genetics by comparing valuation metrics of similar companies.

Myriad Genetics is currently under evaluation in total asset category among related companies.

Myriad Genetics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Myriad Genetics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Myriad Genetics' managers, analysts, and investors.

Environmental

Governance

Social

Myriad Genetics Institutional Holders

Institutional Holdings refers to the ownership stake in Myriad Genetics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Myriad Genetics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Myriad Genetics' value.

		Shares
Goldman Sachs Group Inc	2023-12-31	2.2 M
Sei Investments Co	2023-12-31	2.2 M
Disciplined Growth Investors Inc	2024-03-31	2.1 M
Geode Capital Management, Llc	2023-12-31	1.9 M
D. E. Shaw & Co Lp	2024-03-31	1.3 M
Pictet Asset Manangement Sa	2024-03-31	1.2 M
Nuveen Asset Management, Llc	2023-12-31	1 M
Charles Schwab Investment Management Inc	2024-03-31	986.5 K
Northern Trust Corp	2023-12-31	942.1 K
Blackrock Inc	2023-12-31	14.7 M
Vanguard Group Inc	2024-03-31	10 M

Myriad Fundamentals

	Return On Equity	-0.29
	Return On Asset	-0.066
	Profit Margin	(0.30) %
	Operating Margin	(0.14) %
	Current Valuation	2.14 B
	Shares Outstanding	90.51 M
	Shares Owned By Insiders	2.09 %
	Shares Owned By Institutions	97.91 %
	Number Of Shares Shorted	5.1 M
	Price To Earning	31.95 X
	Price To Book	2.24 X
	Price To Sales	2.33 X
	Revenue	678.4 M
	Gross Profit	476.4 M
	EBITDA	(67.8 M)
	Net Income	(112 M)
	Cash And Equivalents	205.1 M
	Cash Per Share	2.54 X
	Total Debt	145 M
	Debt To Equity	0.11 %
	Current Ratio	3.07 X
	Book Value Per Share	8.40 X
	Cash Flow From Operations	(106.3 M)
	Short Ratio	10.08 X
	Earnings Per Share	(2.80) X
	Price To Earnings To Growth	1.40 X
	Target Price	25.27
	Number Of Employees	2.7 K
	Beta	1.97
	Market Capitalization	2.1 B
	Total Asset	1.2 B
	Retained Earnings	(366.2 M)
	Working Capital	137.4 M
	Current Asset	314.5 M
	Current Liabilities	72.3 M
	Net Asset	1.2 B

About Myriad Genetics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Myriad Genetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Myriad Genetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Myriad Genetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Myriad Genetics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Myriad Genetics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Myriad Genetics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Myriad Genetics Stock:

How To Invest In Myriad

Details

Is Myriad Stock a good investment?

Details

What is Myriad Genetics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Myriad Genetics Piotroski F Score and Myriad Genetics Altman Z Score analysis.

To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.

Note that the Myriad Genetics information on this page should be used as a complementary analysis to other Myriad Genetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Complementary Tools for Myriad Stock analysis

When running Myriad Genetics' price analysis, check to measure Myriad Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Myriad Genetics is operating at the current time. Most of Myriad Genetics' value examination focuses on studying past and present price action to predict the probability of Myriad Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Myriad Genetics' price. Additionally, you may evaluate how the addition of Myriad Genetics to your portfolios can decrease your overall portfolio volatility.

	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Stocks Directory Find actively traded stocks across global markets
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Fundamental Analysis View fundamental data based on most recent published financial statements

Is Myriad Genetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.80)

Revenue Per Share

9.114

Quarterly Revenue Growth

0.116

Return On Assets

(0.07)

Return On Equity

(0.29)

The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Myriad Genetics Stock Total Asset

Myriad Genetics Company Total Asset Analysis

Total Asset

Tangible Assets

+

Intangible Assets

Current Myriad Genetics Total Asset

Myriad Total Asset Driver Correlations

Myriad Total Asset Historical Pattern

Myriad Total Assets

Total Assets

1.45 Billion

Myriad Total Asset Peer Comparison

Myriad Genetics ESG Sustainability

Myriad Genetics Institutional Holders

Myriad Fundamentals

About Myriad Genetics Fundamental Analysis

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Myriad Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY